文献速递自身炎症与 IgG4 相关病

细胞因子靶向治疗下VEXAS综合征的疾病轨迹与糖皮质激素暴露

Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies.
PubMed 文献 · Ann Rheum Dis · 2025-06-27

研究前瞻性随访71例VEXAS患者,评估细胞因子靶向治疗对糖皮质激素使用及临床结局的影响。结果显示抗IL-6R或JAK抑制剂暴露与事件发生率无关联,治疗1年后激素剂量无临床意义下降(<5 mg/日),贫血进展未减缓。

要点

  • p.M41V或p.M41L/T伴CHVAF≥10%者无事件生存劣于p.M41L(HR 5.7)。
  • 抗IL-6R或JAK抑制剂暴露与事件发生率无关联。
  • 中位随访4.8年,平均泼尼松剂量>15 mg/日,仅2.7%访视达≤10 mg/日缓解。

核心结论

  • 细胞因子靶向治疗单独不能改变VEXAS血液学疾病进展风险或显著减少糖皮质激素暴露。
  • 这些数据为未来干预性研究提供了基准。

研究设计与样本

  • 前瞻性随访71例VEXAS患者,回顾性评估实验室结果、糖皮质激素暴露和临床指标与治疗 initiation 的关系。
  • 患者按UBA1变异和典型克隆性造血(变异等位基因分数≥10%,CHVAF≥10%)分层。

主要发现

  • 81.7%患者有抗IL-6R或JAKi暴露。
  • 与p.M41L相比,p.M41V的无事件生存HR为5.7(95%CI 1.5-20.4),p.M41L/T伴CHVAF≥10%的HR为5.7(95%CI 1.6-20.8)。
  • 未观察到事件发生率与抗IL-6R或JAKi暴露的关联。
  • p.M41V基因型贫血、CRP升高和单核细胞减少风险最高。
  • 中位随访4.8年(IQR 3.0-8.1),无论变异或疾病持续时间,患者平均糖皮质激素剂量>15 mg/日泼尼松。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To establish the long-term impact of cytokine-directed therapies on glucocorticoid use and clinical outcomes in Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS). METHODS: Patients with VEXAS were prospectively followed for events of transfusion dependence, haematopoietic stem cell transplantation or death. Laboratory results, glucocorticoid exposure and clinical measures were retrospectively assessed in relationship to treatment initiation with interleukin-6-directed therapies (anti-IL6R) or Janus kinase inhibitors (JAKi). Patients were stratified by UBA1 variants and presence of typical clonal haematopoiesis with variant allele fraction ≥ 10% (CHVAF≥10%). RESULTS: In 71 VEXAS patients (81.7% with anti-IL6R or JAKi exposure), event-free survival differed by genotype and presence of concomitant CHVAF≥10%: p.M41V (HR [95% confidence interval (CI)]: 5.7 [1.5-20.4]) or p.M41L/T with CHVAF≥10% (hazard ratio [HR]: 5.7 [1.6-20.8]) compared to p.M41L. No association between event rates and exposure to anti-IL6R or JAKi was observed. The p.M41V genotype had the highest risk of anaemia, elevated C-reactive protein (CRP) levels, and monocytopenia. Over a median follow-up of 4.8 (interquartile range [IQR] 3.0, 8.1) years, the patients' mean glucocorticoid dose was >15 mg/day prednisone regardless of variant or disease duration. At prospective visits, clinical remission on ≤10 mg/day prednisone was observed in only 2.7% of visits. Treatment with anti-IL6R or JAKi showed no clinically meaningful reduction (<5 mg/day difference) in steroid exposure at 1 year post-treatment. No attenuation in the progression of anaemia was observed in response to anti-IL6R and JAKi. CONCLUSIONS: Cytokine-directed therapies alone do not alter the risk of haematologic disease progression or significantly reduce glucocorticoid exposure in VEXAS. These data provide benchmarks for future interventional studies.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Turturice BA, Fike A, Patel BA, et al. Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies. Ann Rheum Dis. 2025. PMID: 40581580. doi:10.1016/j.ard.2025.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。